Coherus Oncology, Inc. (CHRS)
1.07
+0.02
(+1.90%)
USD |
NASDAQ |
Oct 15, 16:00
1.07
0.00 (0.00%)
After-Hours: 20:00
Coherus Oncology Research and Development Expense (Quarterly) : 20.58M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 20.58M |
| March 31, 2026 | 20.66M |
| December 31, 2025 | 30.08M |
| September 30, 2025 | 26.29M |
| June 30, 2025 | 25.29M |
| March 31, 2025 | 23.31M |
| December 31, 2024 | 19.73M |
| September 30, 2024 | 20.50M |
| June 30, 2024 | 19.41M |
| March 31, 2024 | 26.92M |
| December 31, 2023 | 25.30M |
| September 30, 2023 | 24.01M |
| June 30, 2023 | 22.39M |
| March 31, 2023 | 29.60M |
| December 31, 2022 | 27.97M |
| September 30, 2022 | 45.81M |
| June 30, 2022 | 41.61M |
| March 31, 2022 | 82.92M |
| December 31, 2021 | 49.93M |
| September 30, 2021 | 53.18M |
| June 30, 2021 | 53.87M |
| March 31, 2021 | 202.64M |
| December 31, 2020 | 43.79M |
| September 30, 2020 | 38.15M |
| June 30, 2020 | 25.47M |
| Date | Value |
|---|---|
| March 31, 2020 | 32.50M |
| December 31, 2019 | 33.89M |
| September 30, 2019 | 20.77M |
| June 30, 2019 | 18.88M |
| March 31, 2019 | 18.79M |
| December 31, 2018 | 26.66M |
| September 30, 2018 | 27.70M |
| June 30, 2018 | 26.52M |
| March 31, 2018 | 25.46M |
| December 31, 2017 | 31.43M |
| September 30, 2017 | 42.63M |
| June 30, 2017 | 34.50M |
| March 31, 2017 | 53.78M |
| December 31, 2016 | 59.01M |
| September 30, 2016 | 64.57M |
| June 30, 2016 | 65.54M |
| March 31, 2016 | 65.31M |
| December 31, 2015 | 51.43M |
| September 30, 2015 | 68.22M |
| June 30, 2015 | 56.94M |
| March 31, 2015 | 36.47M |
| December 31, 2014 | 26.87M |
| September 30, 2014 | 18.50M |
| June 30, 2014 | 18.92M |
| March 31, 2014 | 13.94M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | 22.13M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |
| Savara, Inc. | 21.95M |